CX-5461 Clinical Trials (2026): 1 Studies for Advanced Solid Tumor
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 CX-5461 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Advanced Solid Tumor) and 52 total planned enrollment. 1 CX-5461 clinical trial is actively recruiting at 5 U.S. sites across 5 states. Most recent activity: NCT04890613 (Mar 2027).
Where to Participate: All CX-5461 Trial Sites in the U.S. (5 sites across 5 states)
Every actively recruiting CX-5461trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | University of California, Los Angeles | Santa Monica90404 | NCT04890613 | Map |
| FL | H. Lee Moffitt Cancer Center and Research Institute Hospital | Tampa33612-9497 | NCT04890613 | Map |
| MA | Dana Farber Cancer Institute | Boston02215 | NCT04890613 | Map |
| OH | Ohio State University-James Cancer Hospital and Solove Research Institute | Columbus43202 | NCT04890613 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT04890613 | Map |
CX-5461 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting CX-5461 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT04890613 | HRDStudy of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | P1 | Advanced Solid Tumor | 52 | Sep 2021 |
All CX-5461 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT04890613 | HRD | Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | P1 | recruiting | 52 | Senhwa Biosciences, Inc. | Sep 2021 |
CX-5461 clinical trials: frequently asked questions
- How many CX-5461 clinical trials are there?
- 1 CX-5461 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are CX-5461 clinical trials recruiting in 2026?
- Yes — 1 CX-5461 trial is actively recruiting in 2026, with 5 U.S. sites across 5 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is CX-5461 being studied for?
- CX-5461 is being studied for Advanced Solid Tumor. The trials are grouped by indication on this page.
- What phase is CX-5461 in?
- CX-5461 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors CX-5461 clinical trials?
- The lead sponsor across the most CX-5461 trials is Senhwa Biosciences, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming CX-5461as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: